Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma.
Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma.
复制标题
DOI：
10.3892/ijo.27.4.1079
复制
发表时间：
2005-10
影响因子：
5.2
通讯作者：
T. Himoto;S. Kuriyama;Jian-ying Zhang;E. Chan;Y. Kimura;T. Masaki;N. Uchida;M. Nishioka;E. Tan
中科院分区：
文献类型：
--
作者：
T. Himoto;S. Kuriyama;Jian-ying Zhang;E. Chan;Y. Kimura;T. Masaki;N. Uchida;M. Nishioka;E. Tan
使用这些抗原的重组蛋白，在肝细胞癌 (HCC) 患者中分析了针对肿瘤相关抗原 (TAA) 的自身抗体，例如胰岛素样生长因子 II mRNA 结合蛋白 (IMP)、p53、c-myc 和生存素。 86 名 HCC 患者中有 8 名 (9.3%) 具有一种或多种此类自身抗体。然而，除 1 例抗 IMP1 病例外，抗 TAA 的 HCC 患者血清甲胎蛋白 (AFP) 水平均在正常范围内。其中一名 HCC 患者在诊断 HCC 前已存在针对 IMP1、IMP3 和 p53 的自身抗体。这些发现可能表明，抗 TAA 似乎是 AFP 阴性病例中诊断 HCC 的补充血清学标志物，而针对 IMP1、IMP3 和 p53 的自身抗体是 HCC 发展的预测标志物的候选者。
Autoantibodies against tumor-associated antigens (TAAs) such as insulin-like growth factor II mRNA-binding proteins (IMPs), p53, c-myc, and survivin were analyzed in patients with hepatocellular carcinoma (HCC), using recombinant proteins of these antigens. Eight of 86 (9.3%) HCC patients had one or more of these autoantibodies. However, serum alpha-fetoprotein (AFP) levels ranged within normal limits in HCC patients with anti-TAAs except for one case with anti-IMP1. One of the HCC patients had autoantibodies against IMP1, IMP3 and p53 before the diagnosis of HCC. These findings may indicate that anti-TAAs seem to be supplementary serological markers for the diagnosis of HCC in AFP-negative cases and that autoantibodies against IMP1, IMP3 and p53 are candidates for predictive markers of HCC development.